Author: Ehianeta, Teddy S.; Akinyeye, Richard O.; Orege, Joshua I.; Ejeromedoghene, Onome; Adebule, Adeniyi P.; Okonkwo, Bright O.
Title: Old drugs for a new indication: a review of chloroquine and analogue in COVID-19 treatment Cord-id: vy1wzo4i Document date: 2021_6_14
ID: vy1wzo4i
Snippet: As an innovative therapeutic strategy, drug repurposing affords old, approved, and already established drugs a chance at new indications. In the wake of the COVID-19 pandemic and the accompanied urgency for a lasting treatment, drug repurposing has come in handy to stem the debilitating effects of the disease. Among other therapeutic options currently in clinical trials, chloroquine (CQ) and the hydroxylated analogue, hydroxychloroquine (HCQ) have been frontline therapeutic options in most forma
Document: As an innovative therapeutic strategy, drug repurposing affords old, approved, and already established drugs a chance at new indications. In the wake of the COVID-19 pandemic and the accompanied urgency for a lasting treatment, drug repurposing has come in handy to stem the debilitating effects of the disease. Among other therapeutic options currently in clinical trials, chloroquine (CQ) and the hydroxylated analogue, hydroxychloroquine (HCQ) have been frontline therapeutic options in most formal and informal clinical settings with varying degrees of efficacy against this life-threatening disease. Their status in randomized clinical trials is related to the biochemical and pharmacological profiles as validated by in vitro, in vivo and case studies. With the aim to bear a balance for their use in the long run, this review not only synopsizes findings from recent studies on the degrees of efficacy and roles of CQ/HCQ as potential anti-COVID-19 agents but also highlights our perspectives for their consideration in rational drug repositioning and use.
Search related documents:
Co phrase search for related documents- acute respiratory and long term benefit: 1, 2, 3, 4
- acute respiratory and low prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and low toxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and lysosomal endosomal: 1, 2, 3, 4, 5, 6, 7
- acute respiratory and lysosomal endosomal ph: 1, 2
- acute respiratory distress syndrome and liver stage: 1, 2
- acute respiratory distress syndrome and long term benefit: 1
- acute respiratory distress syndrome and low prevalence: 1, 2, 3, 4, 5, 6
- acute respiratory distress syndrome and low toxicity: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and lysosomal endosomal: 1
- acute respiratory syndrome coronavirus and liver stage: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory syndrome coronavirus and long term benefit: 1
- acute respiratory syndrome coronavirus and low prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome coronavirus and low toxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute respiratory syndrome coronavirus and lysosomal endosomal: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome coronavirus and lysosomal endosomal ph: 1, 2
- liver stage and low prevalence: 1, 2
- liver stage and low toxicity: 1
- long term benefit and low prevalence: 1
Co phrase search for related documents, hyperlinks ordered by date